Atezolizumab in non-squamous non-small cell lung cancer

被引：5

作者：

Akamine, Takaki ^{[1
]}

Toyokawa, Gouji ^{[1
]}

Tagawa, Tetsuzo ^{[1
]}

Seto, Takashi ^{[2
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan

[2] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, Fukuoka, Fukuoka, Japan

来源：

JOURNAL OF THORACIC DISEASE | 2018年 / 10卷

关键词：

OPEN-LABEL; 1ST-LINE THERAPY; PHASE-2; TRIAL; EGFR; IMMUNOTHERAPY; PEMBROLIZUMAB; MULTICENTER; BEVACIZUMAB; CHEMOTHERAPY; DOCETAXEL;

D O I：

10.21037/jtd.2018.07.92

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：S3155 / S3159

页数：5

共 23 条

[1] Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study [J].

Besse, Benjamin ;

Le Moulec, Sylvestre ;

Mazieres, Julien ;

Senellart, Helene ;

Barlesi, Fabrice ;

Chouaid, Christos ;

Dansin, Eric ;

Berard, Henri ;

Falchero, Lionel ;

Gervais, Radj ;

Robinet, Gilles ;

Ruppert, Anne-Marie ;

Schott, Roland ;

Lena, Herve ;

Clement-Duchene, Christelle ;

Quantin, Xavier ;

Souquet, Pierre Jean ;

Tredaniel, Jean ;

Moro-Sibilot, Denis ;

Perol, Maurice ;

Madroszyk, Anne-Catherine ;

Soria, Jean-Charles .

CLINICAL CANCER RESEARCH, 2015, 21 (08) :1896-1903

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[4] Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial [J].

Goldberg, Sarah B. ;

Gettinger, Scott N. ;

Mahajan, Amit ;

Chiang, Anne C. ;

Herbst, Roy S. ;

Sznol, Mario ;

Tsiouris, Apostolos John ;

Cohen, Justine ;

Vortmeyer, Alexander ;

Jilaveanu, Lucia ;

Yu, James ;

Hegde, Upendra ;

Speaker, Stephanie ;

Madura, Matthew ;

Ralabate, Amanda ;

Rivera, Angel ;

Rowen, Elin ;

Gerrish, Heather ;

Yao, Xiaopan ;

Chiang, Veronica ;

Kluger, Harriet M. .

LANCET ONCOLOGY, 2016, 17 (07) :976-983

[5] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[6] Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa [J].

Khan, Kabir A. ;

Kerbel, Robert S. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) :310-324

[7] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer [J].

Khunger, Monica ;

Rakshit, Sagar ;

Pasupuleti, Vinay ;

Hernandez, Adrian V. ;

Mazzone, Peter ;

Stevenson, James ;

Pennell, Nathan A. ;

Velcheti, Vamsidhar .

CHEST, 2017, 152 (02) :271-281

[8] Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis [J].

Larsen, Annette K. ;

Ouaret, Djamila ;

El Ouadrani, Karima ;

Petitprez, Amelie .

PHARMACOLOGY & THERAPEUTICS, 2011, 131 (01) :80-90

[9] Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF - Secreting cancer immunotherapy [J].

Li, Betty ;

Lalani, Alshad S. ;

Harding, Thomas C. ;

Luan, Bo ;

Koprivnikar, Kathryn ;

Tu, Guang Huan ;

Prell, Rodney ;

VanRoey, Melinda J. ;

Simmons, Andrew D. ;

Jooss, Karin .

CLINICAL CANCER RESEARCH, 2006, 12 (22) :6808-6816

[10] The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC [J].

Manegold, Christian ;

Dingemans, Anne-Marie C. ;

Gray, Jhanelle E. ;

Nakagawa, Kazuhiko ;

Nicolson, Marianne ;

Peters, Solange ;

Reck, Martin ;

Wu, Yi-Long ;

Brustugun, Odd Terje ;

Crino, Lucio ;

Felip, Enriqueta ;

Fennell, Dean ;

Garrido, Pilar ;

Huber, Rudolf M. ;

Marabelle, Aurelien ;

Moniuszko, Marcin ;

Mornex, Francoise ;

Novello, Silvia ;

Papotti, Mauro ;

Perol, Maurice ;

Smit, Egbert F. ;

Syrigos, Kostas ;

van Meerbeeck, Jan P. ;

van Zandwijk, Nico ;

Yang, James Chih-Hsin ;

Zhou, Caicun ;

Vokes, Everett .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :194-207

← 1 2 3 →